Large gap with delayed quotes
|
Last quote
08/30/2025
-
02:00:00
|
Bid
08/29/2025 -
21:59:59
|
Bid Volume |
Ask
08/29/2025 -
21:59:59
|
Ask Volume |
|---|---|---|---|---|
|
49.33
-0.46
(
-0.92% )
|
49.33
|
400 |
49.36
|
1,100 |
Analysis date: 29.08.2025
Global Evaluation
Slightly negative
Slightly negative
The stock is classified in the slightly negative zone since 15.08.2025.
Interest
Very weak
Very weak
One star since 29.08.2025.
Earnings Rev Trend
Negative
Negative
Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 29.08.2025 at a price of 49.33.
Evaluation
Strongly overvalued
Strongly overvalued
Based on its growth potential and our own criteria, we believe the share price is currently overvalued.
MT Tech Trend
Neutral
Neutral
The stock is currently trading close to its dividend-adjusted forty day moving average (changes between +1.75% and -1.75% are considered neutral). Prior to this, the stock traded above its moving average since 19.08.2025.
4wk Rel Perf
-1.32%
-1.32%
The four-week dividend-adjusted underperformance versus SP500 is 1.32%.
Sensibility
High
High
High, no change over 1 year.
Bear Market Factor
Low
Low
On average, the stock has a tendency to minimize the drops in the index by -0.04%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 4.07%.
Mkt Cap in $bn
3.92
3.92
With a market capitalization between $2 & $8bn, PTC THERAPEUTICS is considered a mid-cap stock.
G/PE Ratio
-0.43
-0.43
A negative ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) indicates that either the forecasted growth is decelerating (negative annualized growth estimate) or the financial analysts are expecting a loss (negative estimated PE).
LT P/E
-45.15
-45.15
The estimated PE is negative: the financial analysts' earnings estimates forecast a loss.
LT Growth
-19.41%
-19.41%
The annualized growth estimate is for the current year to 2027.
Avg. Nb analysts
15
15
Over the last seven weeks, an average of 15 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
114
114
For 1% of index variation, the stock varies on average by 1.14%.
Correlation
0.34
0.34
Stock movements are strongly independent of index variations.
Value at Risk
25.81
25.81
The value at risk is estimated at USD 25.81. The risk is therefore 52.32%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
19.09.2014
19.09.2014